Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and oxadiazoles

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with oxadiazoles in 5 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(oxadiazoles)		Trials
(oxadiazoles)		Recent Studies (post-2010) (oxadiazoles)
9,1561875526,0572572,359

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alessio, P; Bussolino, F; Calvino, R; Fruttero, R; Gasco, A; Ghigo, D; Heller, R; Pescarmona, G; Till, U; Todde, R1
Bosia, A; Bussolino, F; Calvino, R; Gasco, A; Ghigo, D; Heller, R; Pescarmona, GP; Till, U1
Bergamaschi, M; Bongrani, S; Caruso, P; Civelli, M; Gasco, A; Giossi, M; Razzetti, R1
Fox-Robichaud, A; Kubes, P; Payne, D1
Brouckaert, P; Buys, E; Cauwels, A; Janssen, B; Sips, P1

Other Studies

5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and oxadiazoles

ArticleYear
S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.
    Agents and actions, 1993, Volume: 40, Issue:3-4

    Topics: 1-Methyl-3-isobutylxanthine; Acetyltransferases; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic GMP; Endothelium, Vascular; Enzyme Activation; Epoprostenol; Humans; Iloprost; Oxadiazoles; Platelet Activating Factor; Platelet Aggregation Inhibitors; Thrombin; Umbilical Veins

1993
Activation of endothelial guanylate cyclase inhibits cellular reactivity.
    Agents and actions. Supplements, 1995, Volume: 45

    Topics: Arachidonic Acid; Cell Adhesion; Cyclic GMP; Endothelium, Vascular; Enzyme Activation; Epoprostenol; Guanylate Cyclase; Humans; Molsidomine; Nitric Oxide; Nitroprusside; Oxadiazoles; Platelet Activating Factor; Thrombin; Umbilical Veins

1995
The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363.
    British journal of pharmacology, 1996, Volume: 118, Issue:4

    Topics: 1-Methyl-3-isobutylxanthine; Animals; Aorta; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide; Oxadiazoles; Phosphodiesterase Inhibitors; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Vasodilator Agents

1996
Inhaled NO reaches distal vasculatures to inhibit endothelium- but not leukocyte-dependent cell adhesion.
    The American journal of physiology, 1999, Volume: 277, Issue:6

    Topics: Administration, Inhalation; Animals; Capillary Permeability; Cats; Cell Adhesion; Cyclic GMP; Endothelium, Vascular; Enzyme Inhibitors; Histamine; Hydrogen Peroxide; Leukocytes; Leukotriene B4; Lung; Microscopy, Video; Nitric Oxide; Oxadiazoles; Oxidants; Oxidative Stress; P-Selectin; Platelet Activating Factor; Quinoxalines

1999
Anaphylactic shock depends on PI3K and eNOS-derived NO.
    The Journal of clinical investigation, 2006, Volume: 116, Issue:8

    Topics: Anaphylaxis; Animals; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Oxadiazoles; Phosphatidylinositol 3-Kinases; Platelet Activating Factor; Quinoxalines; Serum Albumin, Bovine; Transcription, Genetic

2006